Table 2 A comparison between Rapid (≥ 0.3 mg/dL/day) and Slow (< 0.3 mg/dL/day) groups of serum creatinine trajectory during the time-to-nadir

Age (year)

58.3 ± 15.8 (24–86; 54.4–62.3)

61.7 ± 12.9 (23–82; 57.5–65.9)

Gender

 Men

41 (64.1%)

32 (84.2%)

 Women

23 (35.9%)

6 (15.8%)

BMI (kg/m²)

24.7 ± 4.7 (17.3–36.9; 23.5–25.9)

24.3 ± 5.1 (16.1–35.9; 22.6–26)

Smoking

 Yes

13 (20.3%)

10 (26.3%)

 No

51 (79.7%)

28 (73.7%)

Side of pain

 Bilateral

26 (68.4%)

8 (47.1%)

 Right

6 (15.8%)

5 (29.4%)

 Left

6 (15.8%)

4 (23.5%)

Temperature

37.3 ± 0.5 (36–38.8; 37.1–37.4)

37.1 ± 0.4 (36.5–38.6; 37–37.3)

UOP status at presentation

 Normal

37 (57.8%)

28 (73.7%)

 Low

27 (42.2%)

10 (26.3%)

Loin tenderness

 Unilateral

4 (30.8%)

3 (75%)

 Bilateral

9 (69.2%)

1 (25%)

Pre-drainage dialysis

 Once

9 (60%)

3 (50%)

 More than once

6 (40%)

3 (50%)

Mean parenchymal thickness (mm)

13 ± 1.9 (8–16; 12.5–13.5)

12.4 ± 2 (9.5–16; 11.7–13)

Pathological type of malignancy

 Bladder cancer

32 (50%)

23 (60.5%)

 Prostate cancer

3 (4.7%)

7 (18.4%)

 Colorectal cancer

18 (28.1%)

2 (5.3%)

 Cervical cancer

9 (14.1%)

5 (13.2%)

 Lymphoma

2 (3.1%)

1 (2.6%)

Type of malignancy relative to urinary tract

 Urinary

35 (54.7%)

30 (79%)

 Extraurinary

29 (45.3%)

8 (21%)

Random blood sugar

128.8 ± 54.7 (72–330; 115.1–142.4)

120.9 ± 54.9 (45–315; 102.8–138.9)

Blood PH

7.4 ± 0.1 (7.2–7.5; 7.3–7.4)

7.38 ± 0.05 (7.3–7.5; 7.4–7.4)

PCO₂ (mmHg)

24.4 ± 5.4 (14–36; 23.1–25.8)

24.9 ± 6.1 (15–36; 22.9–26.9)

HCO₃ (mmol/L)

15.2 ± 4.2 (6.7–23; 14.1–16.2)

16.7 ± 4 (11.2–23; 15.4–18)

Acid–base deficit (mmol/L)

− 9 ± 5.5 {− 21 to 1; − 10.34–(− 7.6)}

− 7.3 ± 5.5 (− 15 to 1; − 9.1 to 5.5)

Laterality of drainage

Unilateral

30 (46.9%)

20 (52.6%)

Bilateral

34 (53.1%)

18 (47.4%)

SCr at presentation (mg/dl)

7.5 ± 3.4 (2–17; 6.6–8.3)

4.3 ± 1 (2.2–6.4; 4–4.7)

Post-drainage SCr measures (mg/dl)

SCr at 1st day

6.1 ± 3.1 (1.3–14.8; 5.3–6.8)

3.9 ± 1.1 (1.9–6.2; 3.6–4.3)

SCr at 3rd day

4.8 ± 3.2 (0.8–13; 4–5.6)

3.5 ± 1.1 (1.4–5.7; 3.2–3.9)

SCr at 5th day

3.5 ± 2.6 (0.6–9.1; 2.8–4.1)

3.2 ± 1 (1.5–5.3; 2.8–3.5)

SCr at 7th day

2.7 ± 2.3 (0.5–10.6; 2.1–3.2)

2.7 ± 1 (1–5.6; 2.4–3.1)

SCr at 10th day

2.1 ± 1.5 (0.3–5.2; 1.7–2.4)

2.4 ± 0.8 (1.2–3.9; 2.1–2.6)

SCr at 15th day

1.3 ± 0.75 (0.4–3.5; 1.1–1.5)

1.6 ± 0.55 (0.8–3.9; 1.4–1.7)

SCr at 21st day

1.2 ± 0.62 (0.4–2.5; 1–1.3)

1.5 ± 0.43 (0.8–2.5; 1.4–1.6)

Time-to-nadir SCr (days)

11 ± 5.8 (3–21; 9.5–12.4)

15.4 ± 2.3 (7–21; 14.7–16.2)

SCr normalization rate during 21 days

Normal SCr

42 (65.6%)

16 (42.1%)

High SCr

22 (34.4%)

22 (57.9%)

Pyuria at 1 week after drainage

28.5 ± 28.6 (5–100; 21.4–35.7)

30.61 ± 29.9 (3–100; 20.8–40.5)

Pus cells in urine after drainage /HPF

28.5 ± 28.6 (5–100; 21.4–35.7)

30.6 ± 29.9 (3–100; 20.8–40.5)

SCr-Trs (mg/dL/day)

SCr-Tr during 1st 3 days

0.9 ± 0.7 (− 1–3.3; 0.7–1.1)

0.3 ± 0.2 (0–0.7; 0.2–0.3)

Mode of SCr-Tr during 1st 3 days at 0.3 mg/dL/day value

Rapid SCr-Tr (≥ 0.3 mg/dL/day)

54 (84.4%)

15 (39.5%)

Slow SCr-Tr (< 0.3 mg/dL/day)

10 (15.6%)

23 (60.5%)

Mode of SCr-Tr during 1st 3 days at 0.5 mg/dL/day value

Rapid SCr-Tr (≥ 0.5 mg/dL/day)

48 (75%)

4 (10.5%)

Slow SCr-Tr (< 0.5 mg/dL/day)

16 (25%)

34 (89.5%)

Mode of SCr-Tr during 1st 3 days at 0.7 mg/dL/day value

Rapid SCr-Tr (≥ 0.7 mg/dL/day)

37 (57.81%)

0 (0.0%)

Slow SCr-Tr (< 0.7 mg/dL/day)

27 (42.2%)

38 (100%)

Mode of SCr-Tr during 1st 3 days at 1 mg/dL/day

Rapid SCr-Tr (≥ 1 mg/dL/day)

22 (34.4%)

0 (0%)

Slow SCr-Tr (< 1 mg/dL/day)

42 (65.6%)

38 (100%)

SCr-Tr during 1st week

0.68 ± 0.39 (− 0.53 to 1.7; 0.58–0.78)

0.23 ± 0.15 (− 0.19 to 0.57; 0.18–0.28)

Mean SCr-Tr during time-to-nadir SCr

0.68 ± 0.42 (0.3–2.34; 0.57–0.78)

0.18 ± 0.067 (0.03–0.29; 0.16–0.21)

Mode of SCr-Tr during time-to-nadir SCr at 0.1 mg/dL/day value

Rapid SCr-Tr (≥ 0.1 mg/dL/day)

64 (100%)

35 (92.1%)

Slow SCr-Tr (< 0.1 mg/dL/day)

0 (0%)

3 (7.9%)

Mode of SCr-Tr during time-to-nadir at 0.5 mg/dL/day value

Rapid SCr-Tr (≥ 0.5 mg/dL/day)

38 (59.4%)

0 (0%)

Slow SCr-Tr (< 0.5 mg/dL/day)

26 (40.6%)

38 (100%)

SCr-Tr during 1st 3 days-SCr-Tr during 1st week (mg/dL/day)

0.21 ± 0.5 (− 1.33 to 1.7; 0.09–0.33)

0.05 ± 0.13 (− 0.2 to 0.36; 0.004–0.09)

SCr-Tr during 1st 3 days–SCr-Tr during time-to-nadir SCr (mg/dL/day)

0.2 ± 0.5 (− 1.28 to 1.56; [0.09–0.34)

0.09 ± 0.15 (− 0.17 to 0.51; 0.04–0.14)